### English:
The single nucleotide polymorphism (SNP) **rs121913529** is a well-studied variant located in the **BRCA1 gene**, which is associated with hereditary breast and ovarian cancer syndrome. Below is an analysis of its contribution to polygenic risk scores (PRS):

---

#### 1. Variant Identification:
- **rs number**: rs121913529  
- **HGVS notation**: NM_007294.3(BRCA1):c.5266dupC (p.Gln1756ProfsTer74)  
- **Gene name**: BRCA1  
- **Transcript name**: NM_007294.3  
- **Links**:  
  - [ClinVar entry for rs121913529](https://www.ncbi.nlm.nih.gov/clinvar/variation/17661/)  
  - [dbSNP entry for rs121913529](https://www.ncbi.nlm.nih.gov/snp/rs121913529)  

This variant is a pathogenic frameshift mutation that results in a truncated BRCA1 protein, severely impairing its tumor suppressor function.

---

#### 2. Disease Associations:
- **ClinVar classification**: Pathogenic  
- **Associated diseases**:  
  - Hereditary Breast and Ovarian Cancer Syndrome (HBOC)  
  - Increased risk for other cancers, such as prostate and pancreatic cancer.  
- **Predictive models**: Not applicable for this variant, as it is a high-penetrance mutation rather than a common variant used in PRS.  

This variant is not typically included in polygenic risk scores (PRS) because PRS generally focuses on common variants with small effect sizes, while rs121913529 is a rare, high-impact mutation.

---

#### 3. Literature Evidence:
- Studies have consistently shown that rs121913529 is associated with a significantly increased lifetime risk of breast and ovarian cancer.  
- Relevant publications:  
  - Easton et al., 2015: "Gene-panel sequencing and the prediction of breast cancer risk." [PubMed](https://pubmed.ncbi.nlm.nih.gov/26014596/)  
  - Kuchenbaecker et al., 2017: "Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers." [PubMed](https://pubmed.ncbi.nlm.nih.gov/27553291/)  

---

#### 4. Allele Frequency Comparison:
- **Japanese population**: Extremely rare or absent.  
- **Non-Japanese populations**: Found predominantly in individuals of European ancestry, particularly in families with a history of HBOC.  
- Population-specific differences are due to founder effects and genetic drift.

---

#### 5. GWAS Findings:
- rs121913529 is not typically included in GWAS studies because it is a rare variant with a large effect size. GWAS focuses on common variants with small to moderate effects.  
- However, BRCA1 mutations, including rs121913529, are indirectly considered in risk prediction models for breast and ovarian cancer.

---

### Contribution to PRS:
Polygenic risk scores (PRS) are generally designed to aggregate the effects of common variants with small effect sizes. High-penetrance mutations like rs121913529 are not included in PRS but are instead analyzed separately in clinical genetic testing due to their significant impact on disease risk. For individuals carrying rs121913529, their cancer risk is determined primarily by this mutation rather than by PRS.

---

### Japanese:
一塩基多型（SNP）**rs121913529**は、**BRCA1遺伝子**に位置するよく研究された変異であり、遺伝性乳がんおよび卵巣がん症候群（HBOC）に関連しています。以下は、この変異がポリジェニックリスクスコア（PRS）に与える影響の分析です。

---

#### 1. 変異の識別:
- **rs番号**: rs121913529  
- **HGVS表記**: NM_007294.3(BRCA1):c.5266dupC (p.Gln1756ProfsTer74)  
- **遺伝子名**: BRCA1  
- **転写産物名**: NM_007294.3  
- **リンク**:  
  - [ClinVarエントリー rs121913529](https://www.ncbi.nlm.nih.gov/clinvar/variation/17661/)  
  - [dbSNPエントリー rs121913529](https://www.ncbi.nlm.nih.gov/snp/rs121913529)  

この変異は病原性のあるフレームシフト変異であり、BRCA1タンパク質の腫瘍抑制機能を著しく損ないます。

---

#### 2. 疾患との関連:
- **ClinVar分類**: 病原性  
- **関連疾患**:  
  - 遺伝性乳がんおよび卵巣がん症候群（HBOC）  
  - 前立腺がんや膵臓がんなどのリスク増加。  
- **予測モデル**: この変異は高浸透性の変異であり、PRSで使用される一般的な変異ではないため適用外。  

この変異は、PRSに通常含まれません。PRSは小さな効果サイズを持つ一般的な変異に焦点を当てていますが、rs121913529は希少で高影響の変異です。

---

#### 3. 文献証拠:
- rs121913529は乳がんおよび卵巣がんの生涯リスクを著しく増加させることが一貫して示されています。  
- 関連する出版物:  
  - Easton et al., 2015: "Gene-panel sequencing and the prediction of breast cancer risk." [PubMed](https://pubmed.ncbi.nlm.nih.gov/26014596/)  
  - Kuchenbaecker et al., 2017: "Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers." [PubMed](https://pubmed.ncbi.nlm.nih.gov/27553291/)  

---

#### 4. 対立遺伝子頻度の比較:
- **日本人集団**: 極めて稀または存在しない。  
- **非日本人集団**: 主にヨーロッパ系の家系でHBOCの病歴を持つ個人に見られる。  
- 集団特異的な違いは、創始者効果や遺伝的漂流によるものです。

---

#### 5. GWASの発見:
- rs121913529は希少変異であり、大きな効果サイズを持つため、通常GWAS研究には含まれません。GWASは小から中程度の効果を持つ一般的な変異に焦点を当てています。  
- ただし、BRCA1変異（rs121913529を含む）は、乳がんおよび卵巣がんのリスク予測モデルで間接的に考慮されています。

---

### PRSへの寄与:
ポリジェニックリスクスコア（PRS）は、通常、小さな効果サイズを持つ一般的な変異の影響を集約するように設計されています。rs121913529のような高浸透性変異はPRSには含まれず、臨床遺伝子検査で個別に分析されます。この変異を持つ個人の場合、がんリスクは主にこの変異によって決定され、PRSによるものではありません。

